Gbp9 Activators
Guanylate-binding protein 9 (Gbp9) is a multifunctional protein predicted to enable GTP binding activity and GTPase activity. Its functional roles include participation in the adhesion of symbiont to the host and the defense response to other organisms, with a specific cellular localization in the cytoplasmic vesicle and symbiont-containing vacuole membrane. Gbp9 expression is notable in the meninges and thymus primordium, suggesting its involvement in crucial cellular processes. The activation of Gbp9 is intricately linked to various chemical modulators. Methotrexate, a dihydrofolate reductase inhibitor, indirectly influences Gbp9 by impacting the folate pathway. Wortmannin, a PI3-kinase inhibitor, disrupts PI3K/Akt signaling, potentially regulating Gbp9's GTP binding activity. Tunicamycin, a glycosylation inhibitor, alters Gbp9 activation by influencing protein folding and trafficking. Brefeldin A, a transport disruptor, perturbs vesicular transport, impacting Gbp9's subcellular localization.
Rottlerin, a PKC inhibitor, modulates Gbp9 activation through downstream kinase/phosphatase pathways. SB203580, a p38 MAPK inhibitor, indirectly regulates Gbp9 by affecting stress-related signaling cascades. 5-Fluorouracil, a thymidylate synthase inhibitor, alters nucleotide pools, influencing Gbp9's GTP binding and GTPase activities. Triciribine, an Akt inhibitor, modulates Gbp9 activation through PI3K/Akt signaling. 2-Deoxyglucose, a glycolysis inhibitor, impacts Gbp9 by altering cellular energy status. H89, a PKA inhibitor, modulates Gbp9 activation through PKA-related pathways. Rapamycin, an mTOR inhibitor, influences Gbp9 by regulating mTOR-mediated pathways. Ethacrynic acid, a cotransporter inhibitor, alters Gbp9 activation by influencing ion transport processes. These chemicals exert their effects through intricate pathways, providing a nuanced understanding of Gbp9 regulation. The interplay between these compounds and Gbp9 highlights the complexity of cellular processes and the potential for targeted modulation in a scientific context.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Dihydrofolate reductase inhibitor influencing the folate pathway. By reducing intracellular folate levels, it indirectly modulates Gbp9 activation through altering nucleotide availability, impacting downstream processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3-kinase inhibitor disrupting PI3K/Akt signaling. Affects Gbp9 activation by modulating downstream signaling cascades, potentially regulating its GTP binding activity in response to changes in PI3K-mediated cellular processes. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
N-linked glycosylation inhibitor impacting protein folding in the ER. Alters Gbp9 activation by potentially influencing its trafficking and membrane association, impacting GTPase activity in response to changes in the glycosylation status of the protein. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
ER-to-Golgi transport disruptor targeting ADP-ribosylation factor. Affects Gbp9 activation by perturbing vesicular transport, potentially influencing its subcellular localization and impacting GTPase activity in response to altered vesicular dynamics. | ||||||
Rottlerin | 82-08-6 | sc-3550 sc-3550B sc-3550A sc-3550C sc-3550D sc-3550E | 10 mg 25 mg 50 mg 1 g 5 g 20 g | $84.00 $166.00 $302.00 $2091.00 $5212.00 $16657.00 | 51 | |
PKC inhibitor impacting cellular signaling. Affects Gbp9 activation by potentially influencing downstream kinases and phosphatases, modulating its GTPase activity through alterations in the phosphorylation status mediated by PKC-related pathways. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
p38 MAPK inhibitor affecting cellular stress responses. Modulates Gbp9 activation through indirect regulation of p38 MAPK-mediated pathways, potentially impacting GTP binding activity in response to changes in stress-related signaling cascades. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Thymidylate synthase inhibitor affecting nucleotide synthesis. Influences Gbp9 activation by altering intracellular nucleotide pools, potentially impacting its GTP binding activity and GTPase activity in response to changes in thymidylate synthase-mediated processes. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Akt inhibitor impacting PI3K/Akt signaling. Affects Gbp9 activation by modulating downstream signaling cascades, potentially regulating its GTP binding activity in response to changes in Akt-mediated cellular processes. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
Glycolysis inhibitor influencing energy metabolism. Alters Gbp9 activation by potentially impacting cellular energy status, modulating its GTP binding activity and GTPase activity in response to changes in glycolysis-mediated processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
mTOR inhibitor impacting protein synthesis. Influences Gbp9 activation by modulating downstream mTOR-mediated pathways, potentially regulating its GTP binding activity in response to changes in protein synthesis-related cellular processes. | ||||||